Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZTI-01 versus piperacillin/tazobactam for complicated urinary tract infection
2015-003372-73Phase 2Completed
- Sponsor
- Zavante Therapeutics
- Start
- Dec 2015
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in complicated urinary tract infection (cUTI) and acute pyelonephritis comparing ZTI-01 with Piperacillin/tazobactam (2 arms). Primary endpoint: Overall success at test of cure in m-mITT population. Started Dec 2015; status: completed.
02
Drugs
fosfomycinpiperacillin + tazobactam
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on 2015-003372-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003372-73.